(Q38149725)

29 August 2017

At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies (English)

1 reference

29 August 2017

1 reference

Pietro Merli

2

0 references

Sergio Rutella

object named as

Sergio Rutella

series ordinal

3

0 references

Franco Locatelli

series ordinal

1

object named as

Franco Locatelli

1 reference

29 August 2017

4 October 2013

1 reference

Journal of Leukocyte Biology

29 August 2017

1 reference

29 August 2017

94

1 reference

29 August 2017

6

1 reference

29 August 2017

1141-1157

1 reference

Hematopoietic stem-cell transplantation

29 August 2017

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Haematopoietic cell transplantation as immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Understanding and harnessing the graft-versus-leukaemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Minor histocompatibility antigens--big in tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Immunotherapy of cancer through targeting of minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Searching for alternative hematopoietic stem cell donors for pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Haploidentical hematopoietic transplantation: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Determinants of antileukemia effects of allogeneic NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Innate or adaptive immunity? The example of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recogn

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificitie

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Receptors for HLA class-I molecules in human natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

MHC class I molecules and KIRs in human history, health and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

NK cell MHC class I specific receptors (KIR): from biology to clinical intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Association of γδ T cells with disease severity and mortality in septic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Granzyme A produced by γ(9)δ(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

IL-17-producing γδ T cells and innate lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Regulation of cutaneous malignancy by gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Gammadelta T cells and the lymphoid stress-surveillance response

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Skin gammadelta T-cell functions in homeostasis and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

V gamma 9V delta 2 T cell response to colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Peripheral gamma delta T-cell deficit in nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

3-Formyl-1-butyl pyrophosphate A novel mycobacterial metabolite-activating human gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Escherichia coli produces phosphoantigens activating human gamma delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Human cord blood γδ T cells expressing public Vγ2 chains dominate the response to bisphosphonate plus interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct γδ and αβ T cell responses in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Cytokine activation induces human memory-like NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0613343

21 January 2018

Identifiers

DOI

10.1189/JLB.0613343

1 reference

29 August 2017

1 reference

PubMed ID

24096380